Xcelience Launches New Service to Enhance Its Preformulation & Formulation Capabilities
Summary
The company has earned a solid reputation of accelerating early development activities to speed potential drugs to clinical trials while applying unparalleled scientific knowledge and experience.The company brings together the industrys most experienced and talented scientists, consistently and efficiently moving compounds through the research and development continuum to regulatory approval.The lab uses only state-of-the-art equipment, highlighted by the patented Xcelodose® which fills API directly to capsules (Xcelodose is a registered trademark of Capsugel BVBA).www.xcelience.com Media Contact: Oniel Delva Teasdale Worldwide 813.868.1529 oniel@teasdaleworldwide.com ### Tampa, FL, May 08, 2008 --( PR.com )-- Xcelience, a leader in early drug development services, recently announced its expanded offering of X-ray Diffraction (XRD) capabilities to support clients’ needs in the areas of preformulation and formulation development.“At the urging of several of our clients, we have committed to the purchase of an XRD instrument to enhance our overall capabilities in formulation analysis, polymorph identification, salt screen and selection, and crystallinity determination,” states Mark Cappucci, Team Leader for Preformulation and Formulation.This information can be provided to aid early development activities with use of a small amount of sample which is nondestructive to the sample being evaluated.The lab uses only state-of-the-art equipment, highlighted by the patented Xcelodose® which fills API directly to capsules (Xcelodose is a registered trademark of Capsugel BVBA).